Stem Cell–Based Transcatheter Aortic Valve Implantation First Experiences in a Pre-Clinical Model by Emmert, Maximilian Y. et al.
L
C
V
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 5 , N O . 8 , 2 0 1 2
© 2 0 1 2 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 2 . 0 4 . 0 1 0PRE-CLINICAL RESEARCH
Stem Cell–Based Transcatheter
Aortic Valve Implantation
First Experiences in a Pre-Clinical Model
Maximilian Y. Emmert, MD,*†‡ Benedikt Weber, MD,*† Petra Wolint,*†
Luc Behr, VDM, PHD,¶ Sebastien Sammut, PHD,*¶ Thomas Frauenfelder, MD,§
aura Frese, PHD,*† Jacques Scherman, MD,‡ Chad E. Brokopp, PHD,*†
hristian Templin, MD, Jürg Grünenfelder, MD,†‡ Gregor Zünd, MD,*†‡
olkmar Falk, MD,‡ Simon P. Hoerstrup, MD, PHD*†‡
Zurich, Switzerland; and Paris, France
Objectives This study sought to investigate the combination of transcatheter aortic valve implanta-
tion and a novel concept of stem cell-based, tissue-engineered heart valves (TEHV) comprising mini-
mally invasive techniques for both cell harvest and valve delivery.
Background TAVI represents an emerging technology for the treatment of aortic valve disease. The
used bioprostheses are inherently prone to calciﬁc degeneration and recent evidence suggests even ac-
celerated degeneration resulting from structural damage due to the crimping procedures. An autologous,
living heart valve prosthesis with regeneration and repair capacities would overcome such limitations.
Methods Within a 1-step intervention, trileaﬂet TEHV, generated from biodegradable synthetic scaf-
folds, were integrated into self-expanding nitinol stents, seeded with autologous bone marrow
mononuclear cells, crimped and transapically delivered into adult sheep (n  12). Planned follow-up
was 4 h (Group A, n  4), 48 h (Group B, n  5) or 1 and 2 weeks (Group C, n  3). TEHV function-
ality was assessed by ﬂuoroscopy, echocardiography, and computed tomography. Post-mortem anal-
ysis was performed using histology, extracellular matrix analysis, and electron microscopy.
Results Transapical implantation of TEHV was successful in all animals (n  12). Follow-up was
complete in all animals of Group A, three-ﬁfths of Group B, and two-thirds of Group C (1 week, n 
1; 2 weeks, n  1). Fluoroscopy and echocardiography displayed TEHV functionality demonstrating
adequate leaﬂet mobility and coaptation. TEHV showed intact leaﬂet structures with well-deﬁned
cusps without signs of thrombus formation or structural damage. Histology and extracellular matrix
displayed a high cellularity indicative for an early cellular remodeling and in-growth after 2 weeks.
Conclusions We demonstrate the principal feasibility of a transcatheter, stem cell–based TEHV implan-
tation into the aortic valve position within a 1-step intervention. Its long-term functionality proven, a
stem cell–based TEHV approach may represent a next-generation heart valve concept. (J Am Coll
Cardiol Intv 2012;5:874–83) © 2012 by the American College of Cardiology Foundation
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875The therapy options for patients with valvular heart disease
are undergoing rapid changes and in addition to conven-
tional, surgical valve replacement, representing the standard
of care for several decades, transcatheter aortic valve tech-
niques have entered the clinical routine, representing an
efficient alternative for the treatment of elderly high-risk
patients (1–4). Given sufficient long-term safety, it can be
predicted that these minimally invasive techniques may have
a major impact on the treatment strategy of patients with
valvular heart disease.
However, despite this rapid technical progress, the currently
available prostheses for transcatheter approaches are biopros-
thetic with the known disadvantages comprising progressive
calcification and degeneration. Furthermore, recent evidence
suggests even accelerated degeneration resulting from struc-
tural damage due to the crimping procedures (5,6).
An autologous, living heart valve prosthesis created by
tissue-engineering technologies with regeneration and re-
pair capacities would overcome such limitations (7). A
clinically relevant heart valve tissue-engineering (HVTE)
concept would ideally comprise minimally invasive techniques
for both cell harvest and valve implantation. We have
demonstrated the technical feasibility of combining the
concept of HVTE and transapical delivery into the pulmo-
nary position of adult sheep (8). Thereafter, in a recent proof-
f-concept study, we introduced a novel and clinically highly
elevant concept of in vivo implantation of autologous bone
arrow mononuclear cell (BMMC)-derived tissue-engineered
eart valves (TEHV) in a primate model (9). Following
ecent U.S. Food and Drug Administration approval (10),
echniques to generate tissue-engineered vascular grafts by
sing BMMC without any phase of in vitro culturing or
xpansion (11–15) are entering the clinical arena. Based on
hese techniques, we successfully generated and implanted
utologous BMMC-derived TEHV in a 1-step intervention
omprising cell harvest, in vitro engineering, and transapical
elivery (9). However, except for an acute, technical feasi-
ility study using a modified Hufnagel procedure (16) to
mplant TEHV into the descending aorta in an ovine model
17), chronic studies of successful TEHV implantations
ave only been reported for the low-pressure system in the
ulmonary position (8,9,18).
The aim of this study was to assess the principal feasibility of
mplanting stem cell–based TEHV into the aortic valve
osition using a transcatheter, 1-step interventional approach.
eside the technical feasibility of the deployment of a TEHV
n the aortic position, the major endpoints of this study were
he assessment of the valve functionality and initial tissue-
emodeling phenomena of TEHV in the aortic position.
ethods
Experimentation approval. All animals received humane care
in compliance with the “Principles of Laboratory Animal-Care” as well as with the “Guide for the Care and Use of
Laboratory Animals” published by the National Institutes of
Health (19). All procedures were approved by the Institutional
Ethics Committee (approval no. 11-15/2011).
Study design. The study aim was to assess the principal
easibility of implanting stem cell–based TEHV into the
rthotopic, aortic valve position using a transcatheter, 1-step
nterventional approach (Fig. 1, Online Fig. 1). The study
nimals (adult sheep, n  12) were divided into 3 groups:
Group A (follow-up: 4 h, n  4); Group B (follow-up: 48 h,
n  5); and Group C (follow-up: 1 and 2 weeks, n  3)
(Fig. 2).
In the first set of experiments, the animals of Group A
(n  4) were used in an acute fashion (follow-up: 4 h) to
establish the technical feasibility of transapical TEHV
implantation into the orthotopic, aortic position with a
specific focus on technical aspects, such as device insertion,
stepwise delivery, and optimal positioning considering the
anatomical condition of the aortic annulus, the aortic
root, and the coronaries. To assess TEHV stability and
functionality as well as early tissue reaction and remod-
eling in the systemic pressure
system, the other animals were
planned to be followed up for
either 48 h (Group B, n  5)
or 1 and 2 weeks (Group C,
n  3) (Fig. 2).
Scaffold fabrication. Trileaflet
eart valve scaffolds were fabri-
ated as previously described
9,17) (Online Appendix).
Isolation, characterization, and
differentiation of ovine BMMC. See
nline Figures 1 and 2.
Seeding of ovine BMMC. Fibrin was used as a cell carrier to
eed BMMC onto both sides as well as on the conduit of
he stented heart valve scaffolds (1.73  0.47  106
cells/cm2 valve leaflets) (Sigma-Aldrich, St. Louis, Mis-
ouri), before the stented TEHV was loaded into the
elivery device by crimping the outer diameter from 25 mm
own to 8 mm (Online Appendix).
Pre-operative assessment, planning, and sizing. Before im-
plantation, all sheep underwent transthoracic echocardiog-
raphy (TTE) to adapt the ideal stent size to each animal.
Before starting the implantation procedure, the following
parameters were measured by intraoperative angiography to
reconfirm the ideal stent size: diameters of the aortic annulus,
sinus portion, the sinus-tubular junction, and the brachioce-
phalic trunc, as well as the distance to the brachiocephalic trunc
and the height of the sinus portion (Table 1). Animals with an
annulus between 22 mm and 23 mm received a 25 mm stented
TEHV (n 8), whereas animals with an annulus of 24 mm to
Abbreviations
and Acronyms
BMMC  bone marrow
mononuclear cell(s)
HVTE  heart valve tissue
engineering
TEHV  tissue-engineered
heart-valve(s)
TTE  transthoracic
echocardiography25 mm received a 27 mm stented TEHV (n  4).
ation t
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876Transcatheter implantation of stem cell–based TEHV into the
aortic valve position. TEHV were transapically delivered
into the aortic valve position via a mini sternotomy (Fig. 1).
The valves were crimped and loaded onto a custom-made,
guidewire-inducing system (outer diameter  8 mm). The
Figure 1. Stem Cell–Based, TEHV Implantation Into the Aortic Valve Positi
Bone marrow is aspirated from the sternum into a heparinized syringe (1) and
ples on a histopaque density gradient (2). The BMMC are seeded onto the ste
engineered heart valve (TEHV) is loaded into the delivery device by crimping t
duration of the entire procedure, starting from cell harvest until TEHV-implant
Figure 2. Study DesignAnimal distribution and follow-up (FU). *In Group C, 1 animal completed 1 week FUapex of the left ventricle was punctured after 5/0 Prolene
(Ethicon Inc., Norderstedt, Germany) pledged, purse-string
sutures were placed. TEHV were delivered into the aortic
valve position under fluoroscopic control (OEC 9900 Elite,
GE Healthcare, Fairfield, Connecticut). After the stepwise
a Transcatheter, 1-Step Interventional Approach
marrow mononuclear cells (BMMC) are obtained by centrifuging the sam-
eart valve scaffolds using ﬁbrin as a cell carrier (3). Thereafter, the tissue-
ter diameter down to 8 mm and transapically delivered (4). The mean
akes approximately 2 h.on via
bone
nted h
he ouand 1 animal completed 2 weeks FU.
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877opening and positioning of the distal part of the stent in the
aortic root under fluoroscopic control, the proximal part of
the stent was instantly delivered. The appropriate placement
and functionality of the implanted valve was confirmed by
contrast angiography before the device was carefully re-
moved and the purse-string sutures were tightened.
Assessment of stent positioning and TEHV functionality.
Stent positioning was controlled using angiography and com-
puted tomography (Siemens, Munich, Germany). In vivo
functionality was evaluated using intraoperative, epicardial 2-
and 3-dimensional echocardiography (iE33W xMATRIX
Ultrasound, Philips Healthcare, Best, the Netherlands). TTE
was serially performed until the animal was sacrificed. Three-
dimensional computed tomography reconstruction and volume
rendering were performed using the OsiriX Image Processing
Software (OsiriX Mac OSX, version 3.8.1).
Post-operative care and follow-up. Anticoagulation was
one with aspirin 100 mg/day and a clinical checkup was
erformed daily until sacrifice. The animals were sacrificed
pplying potassium euthanization and exsanguination.
hereafter, the hearts were harvested and the TEHV were
xcised for in vitro analysis.
Histology and scanning electron microscopy. Tissue sam-
les of the explanted TEHV were analyzed qualitatively
ia histology and scanning electron microscopy (Online
ppendix).
Quantitative explant tissue analysis. Explanted TEHV were
yophilized and analyzed by biochemical assays for total
eoxyribonucleic acid and glycosaminoglycans content
Online Appendix).
Statistical analysis. Quantitative data are presented as mean
D (SPSS, version 17.0, IBM, Somers, New York).
esults
Cell isolation, characterization, and preparation of TEHV. Ovine
BMMC were evaluated by flow cytometric analysis. Surface
marker expression of CD29 (59.0  7.0%) and CD44
(61.0  16.7%) was detected. Less than 4% of the cells
were positive for CD31 (3.7  1.7%), CD34
Table 1. Pre-Operative Data and Angiographic Measurements
Body weight, kg 53.3 8.1
Diameter AA on pre-op TTE, mm 22.1 0.7
Diameter AA, mm 22.7 1.0
Diameter BCT, mm 15.2 1.4
Distance to BCT, mm 45.1 2.7
Diameter SP, mm 28.3 2.0
Diameter STJ, mm 24.5 1.4
Height of SP, mm 13.3 2.0
Values are mean SD.
AA aortic annulus; BCT brachiocephalic trunc; pre-op pre-operative; SP sinus portion;
STJ sinus-tubular junction; TTE transthoracic echocardiography.3.7  1.0%), and CD166 (3.5  4.4%) and no expressionof Stro-4 was observed (Online Fig. 2A). Ovine mesenchy-
mal stem cells were positive for CD29 (92.3  2.1%),
CD44 (24.3  11.9%), CD166 (73.0  14.2%), and Stro-4
(93.7  14.2%). In contrast, low expression of the hema-
topoietic lineage markers CD31 (1.3  0.9%) and CD34
(2.1  1.8%) was observed (Online Fig. 2B). The results of
he ovine mesenchymal stem cells phenotype were con-
rmed using immunofluorescence (Online Fig. 2C). Ovine
esenchymal stem cells displayed a characteristic spindle-
haped fibroblastic morphology (Online Fig. 2D). Their
ifferentiation potential was demonstrated by inducing cells
o specific lineages: adipogenic; osteogenic; and chondro-
enic (Online Fig. 2D).
Transcatheter aortic valve implantation of stem cell–based TEHV.
DELIVERY, POSITIONING, AND INTRAOPERATIVE COMPLI-
CATIONS. Transcatheter aortic valve implantation of stem
ell–based TEHV could be performed successfully in all
nimals (n  12) (Fig. 3, Online Video 1). The aortic root
as visualized (Fig. 3A) before the loaded delivery device
as inserted and positioned (Fig. 3B). Under instant fluo-
oscopic control, the TEHV was stepwise delivered begin-
ing with the deployment of the distal part (Figs. 3C and 3D)
ollowed by the proximal part (Fig. 3E). Immediately after
ull deployment, coronary perfusion (Fig. 3F) and valve
unctionality was confirmed in the fluoroscopy (Fig. 3G).
he animals remained hemodynamically stable during the
ntire procedure. Device removal was uneventful and no
ajor complications, such as bleeding or cardiac arrhyth-
ia occurred. As on fluoroscopy (Figs. 3A to 3G,
nline Video 1) and as confirmed on computed tomogra-
hy (Online Figs. 3A to 3G), TEHV could be successfully
laced into the aortic valve position, thereby fully excluding
he native leaflets while not compromising the coronary
erfusion (Fig. 3D to 3G, Online Video 1). In 1 animal of
roup B the TEHV appeared to be placed too proximal
nto the left ventricular outflow tract. Consecutively, after a
ew hours, it further migrated into the left ventricle and the
nimal was sacrificed due to beginning acute left heart
ailure. Another animal of Group B had to be terminated
fter successful delivery due to severe valvular leaflet dys-
unction displaying severe central regurgitation immediately
fter implantation.
The mean duration from cell harvest until TEHV loading
as 64  8 min and the mean crimping time until
ransapical delivery was 12  6 min. The mean duration of
he entire procedure, starting from cell harvest until TEHV
mplantation was 109  14 min (Table 2).
Performance of TEHV and acute echocardiography ﬁndings.
Acute TEHV functionality and mobility was controlled via
fluoroscopy (Fig. 3G) and epicardial echocardiography.
Except for the 2 terminated animals, in all other study
animals (n 10), a sufficient opening and closing pattern of
the TEHV was observed and the loading pressure of the
systemic circulation was well tolerated (Figs. 4A and 4B,
te leaﬂ
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878Online Video 2A). TEHV functionality was confirmed in
the 2-dimensional color mode and the 3-dimensional
mode, demonstrating good leaflet mobility and coapta-
tion (Figs. 4C to 4G, Online Videos 2B and 2C). The
mean transvalvular gradient was 8.4  2.0 mm Hg and
he mean effective orifice area was 1.4  0.1 cm2 (Table 2).
Only 1 animal displayed a mild mitral regurgitation, and
none of the animals showed central aortic regurgitation.
In contrast, in 40% of the animals, an at least mild
paravalvular leakage was present (Table 2), which was
related to the stent shape and design, but not to the
Figure 3. Fluoroscopy-Guided Transapical Delivery of Stem Cell–Based TEH
The aortic root was visualized (A) before the loaded delivery device was inserted
valve (TEHV) was stepwise delivered beginning with the deployment of the distal
coronary perfusion (F) and valve functionality (G) was conﬁrmed. The animals rem
successfully placed into the aortic valve position, thereby fully excluding the nativTEHV itself.Early post-operative period, complications, and follow-up.
Except the 2 terminated animals, all other animals of Group B
(3 of 5) and Group C (3 of 3) tolerated the procedure very
well without any hemodynamic compromise and could be
awakened immediately. Despite of an uneventful TEHV
delivery and an excellent TEHV functionality without any
signs of regurgitation or paravalvular leakage, 1 animal of
Group C died due to acute stent dislocation. All other study
animals were monitored regularly and received regular doses
of aspirin until the planned harvest.
The 2 remaining animals of Group C (planned to be
the Aortic Valve Position
sitioned (B). Under instant ﬂuoroscopic control, the tissue-engineered heart
and D) followed by the proximal part (E). Immediately after full deployment,
hemodynamically stable during the entire procedure and the TEHV could be
ets while not compromising the coronary perfusion. See Online Video 1.V Into
and po
part (C
ainedfollowed-up for 1 and 2 weeks) displayed a sufficient TEHV in
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879vivo functionality on TTE and transesophageal echocardiog-
raphy at 1 week with a mean transvalvular gradient of 8.0 1.7
m Hg and a mean effective orifice area of 1.5  0.1 cm2.
Therefore, it was decided to harvest 1 animal at 1 week
nd to keep the last remaining animal for an additional
eek to gain further insight into the early remodeling
rocess. The remaining animal was clinically followed-up
Table 2. Intraoperative Data and Echocardiography Measurements
After Implantation
Duration from cell harvest to TEHV loading, min 64 8
Crimping time until TEHV delivery, min 12 6
Duration of the entire 1-step procedure, min 109 14
TVG mean, mm Hg 8.4 2.0
TVG peak, mm Hg 16.9 5.8
EOA, cm2 1.4 0.1
Central aortic regurgitation None
Paravalvular leakage* 2.1 1.7
Regurgitation of mitral valve* None†
Leaﬂet motion Normal
Cardiac output, l/min 5.7 1.2
Values are mean  SD. *Regurgitation/paravalvular leakage grading: 0  none; 1  trivial; 2 
mild; 3moderate; 4 severe. †Except 1 animal displaying mitral regurgitation grade 2.
EOA  effective orifice area; TEHV  tissue-engineered heart valve; TVG  transvalvular
gradient.
Figure 4. Performance of TEHV and Echocardiography Findings
Tissue-engineered heart valve (TEHV) functionality and mobility was controlled
pressure of the systemic circulation adequately and demonstrated a sufﬁcient
conﬁrmed in the 2-dimensional color mode (C, D, and insets) and in the 3-di
Online Videos 2A, 2B, and 2C.aily and the pre-final TTE control on day 10 before the
lanned harvest displayed sufficient TEHV performance.
hile preparing for the final assessment and harvest, the
nimal suddenly decompensated hours before the planned
acrifice at day 14 due to a sudden stent dislocation.
Explant macroscopy. Except the animal that had to be termi-
ated due to sudden valve dysfunction, all other TEHV (n 
1) displayed intact leaflet structures with well-defined cusps
nd sufficient coaptation, without signs of thrombus formation,
hickening, shrinking, or structural damage (Figs. 5A and 5B).
he TEHV harvested at 1 and 2 weeks after implantation
ppeared to be well integrated into the surrounding tissue by
omplete tissue covering of the stent frame (Fig. 5C). The
EHV explanted at 2 weeks showed tissue formation and
oaptation in 2 fully intact leaflets. The third leaflet (non-
oronary) displayed a thin fissure that we assume was
ossibly related to the harmful explantation procedure as the
tent was completely entrapped in the mitral valve and
dequate trileaflet TEHV functionality was confirmed on
TE 3 days before.
Explant microscopy. After explantation, harvested tissues
were analyzed using scanning electron microscopy, histol-
ogy, and extracellular matrix analysis. In scanning electron
microscopy, acute TEHV explants revealed a surface with
picardial and transesophageal echocardiography. TEHV tolerated the loading
ation (A, B, and insets). TEHV functionality and absence of regurgitation was
onal mode demonstrating adequate leaﬂet mobility (E to G, and insets). Seevia e
coapt
mensi
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880fibrin reaction characterized by thrombocyte aggregation as
well as leukocyte attachment (Online Fig. 4). This was also
confirmed in histology, where acute explants showed clear
cellular infiltrates and fibrin formation in hematoxylin and
eosin staining (Figs. 6A to 6D). Interestingly, this cellularity
only slightly increased in the tissues of the 24-h explants,
whereas all later explant stages—including the 1-week and
the 2-week explant tissues—showed a clearly increased
cellularity (Figs. 6E to 6L). This observation was also
supported by the extracellular matrix analysis, which showed
increasing deoxyribonucleic acid and glycosaminoglycan
values in the TEHV with increasing time in vivo (Online
Figs. 5A and 5B).
Discussion
TAVI, which has been recently implemented into clinical
Figure 5. Explant Macroscopy of TEHV
Explanted tissue-engineered heart valves (TEHV) displayed intact leaﬂet
structures with well-deﬁned cusps and sufﬁcient coaptation, without signs
of thrombus formation, thickening, shrinking, or structural damage from
the lower view (A and inset) and the upper view (B). The TEHV harvested
at 1 and 2 weeks after implantation appeared to be well integrated into
the surrounding tissue by complete tissue covering of the stent-frame (C).routine as an attractive alternative for conventional aorticvalve replacement, is expected to have a major impact on the
management of valvular heart disease (1–4). Although these
techniques are primarily applied to elderly, high-risk pa-
tients (1,3), the extension of indication for younger patients
is awaited for the near future. However, despite the tremen-
dous potential of transcatheter techniques, the currently
used valvular prostheses for these approaches are biopros-
thetic and all major disadvantages apply, including progres-
sive calcification and functional degeneration (9,20–22).
The concept of TEHV has been repeatedly suggested as
a potential solution to overcome the limitations of currently
used bioprostheses (21,23). The use of living, autologous
cell–based valvular constructs with the capacity of growth
and regeneration may be significantly beneficial for both the
congenital and adult settings. Numerous tissue-engineering
concepts as well as cell sources are under evaluation for their
clinical relevance, and we have recently demonstrated the
principal feasibility of combining the concept of HVTE and
transcatheter approaches in a pre-clinical large-animal
model (8). However, so far, most of these concepts require
extensive technical, logistical, and financial efforts, limiting
their broad implementation into the clinical arena. There-
fore, more simplicity is mandatory for an efficient transla-
tion into the clinical arena. A clinically relevant HVTE
concept comprises minimally invasive techniques for both
cell harvest and valve delivery.
We have recently introduced a new concept of combining
autologous, TEHV, and transcatheter approaches in a
1-step procedure (9,17). Based on various previous animal
studies and clinical pilot trials (12,14,15) to generate
BMMC-derived tissue-engineered vascular grafts, in recent
proof-of-concept studies, we were able to show the
successful implantation of autologous BMMC-derived
TEHV in a 1-step intervention into the pulmonary
position in a primate model (9), as well as in the
descending aorta using a modified Hufnagel procedure in
an acute ovine model (17).
In this study, and for the first time, we demonstrate the
feasibility of this 1-step procedure comprising minimally
invasive cell harvest and transapical delivery for the aortic
valve position successfully replacing aortic valves in an ovine
model. With the help of an improved catheter system
allowing for orthotopic, aortic valve implantation, we were
able to further develop and adapt this novel, clinically,
highly relevant 1-step procedure for the high-pressure
circulation. Our data indicate that BMMC-based TEHV
can be successfully implanted into the aortic position exhib-
iting competent valve functionality and leaflet coaptation
sufficiently withstanding the systemic pressure load, whereas
any signs of valvular rupture, tear, or structural damage were
absent.
Importantly, this study reveals that the TEHV fully
accepted the systemic pressure responding with a high
degree of early cellularization indicative for an active and
HV 
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881extensive tissue formation and remodeling process. As
previously described, sufficient hemodynamic loading ap-
pears to play a key role in tissue remodeling and formation
and is a well-established mechanism (24). The histological
findings of this study are supported by the interesting
observation in our recent study that elucidated the crucial
impact of sufficient hemodynamic loading on functional
tissue remodeling in a nonhuman primate model. In con-
trast to orthotopically delivered TEHV fully excluding the
native leaflets, TEHV that were implanted into the supra-
valvular position—not excluding the native leaflets and
thereby being fully unloaded—lacked significant leaflet
structure, being indicative for complete absence of tissue
formation as well as BMMC-mediated remodeling pro-
cesses (9).
The underlying molecular mechanisms of autologous
BMMC-based tissue remodeling appear to be complex and
have not been completely understood so far. Recent studies
suggest a multifactorial, BMMC-mediated chemoattractive
process (9,13,22,25,26). This extensive, paracrine process
appears to involve numerous cells, including monocytes as
well as mediator cytokines controlling the different steps of
remodeling and tissue formation (9,13,22,25,26). In the
setting of tissue-engineered vascular grafts, Roh et al. (13)
recently demonstrated that seeded BMMC secrete signifi-
Figure 6. Histological Analysis of TEHV Explants
On histology, acute explants showed clear cellular inﬁltrates and ﬁbrin formati
estingly, this cellularity only slightly increased in the tissues of the 24-h explan
showed a clearly increased cellularity (E to L) (magniﬁcation 5 and 10). TEcant amounts of monocyte chemoattractant protein-1 andlead to an increased early monocyte recruitment. Impor-
tantly, they also showed that the seeded BMMC were no
longer detectable within a few days after implantation,
suggesting that the scaffolds were initially repopulated by
host monocytes by a monocyte chemoattractant protein-1–
mediated process (13). In line with that, the recent study of
Hibino et al. (25,26) confirmed the early absence of seeded
BMMC declining to 1% after 2 weeks indicating that the
bone marrow does not represent the significant source of
endothelial or smooth muscle cells that comprise the newly
formed vessel. In contrast, the adjacent vessel wall appeared
to be the primary source of these cells forming the major
part of the neotissue. The investigators concluded that
tissue-engineered constructs function by mobilizing the
body’s innate healing capabilities to “regenerate” neotissue
from pre-existing committed tissue cells (25). The mecha-
nism of a BMMC-mediated chemoattractive process ap-
pears to be confirmed in the present study, indicating an
early and extensive remodeling process primarily character-
ized by an early monocytic infiltration that may even be
accelerated due to the systemic pressure loading.
Another interesting observation in this study was that
macroscopically the TEHV did not display any sign of
thickening or shrinking when compared with the previous
reports in sheep (8,18) or primates (9) that presented with
hematoxylin and eosin staining (A to D) (magniﬁcation 5 and 10). Inter-
ages not shown), whereas all later explant stages at 1 week and 2 weeks
tissue-engineered heart valve(s).on in
ts (imfunctional, but shortened leaflets limiting an optimal coap-
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882tation area. A potential reason may be reflected in the fact
that this study was the first trial performed in the high-
pressure circulation, whereas all other studies have been
performed in the low-pressure pulmonary circulation
(8,9,18). Although highly speculative, the high-pressure
environment may play a key role in this regard and may
prevent the TEHV from shrinking and thickening. Con-
secutive studies will be mandatory to further elucidate the
important key issue of shrinking and to determine the role
of pressure in this regard.
Study limitations. Based on this proof-of-concept study
demonstrating the principal feasibility of transcatheter aor-
tic valve replacement using BMMC-based valves in a 1-step
procedure, long-term studies are mandatory to further assess
the fate and the underlying remodeling mechanisms of such
TEHV. Furthermore, the role of the seeded BMMC and
the associated multifactorial, chemoattractive remodeling
process needs to be systematically evaluated to define quality
criteria of tissue formation representing a key prerequisite
for a safe translation into the clinical setting. Finally,
additional effort is needed to improve the stent design to
further minimize the principle problem of paravalvular
leakage and stent dislocation that is associated with current
transcatheter approaches, as it was also encountered in the
present study.
Conclusions
Considering the tremendous clinical potential of a BMMC-
based tissue-engineering approach that has already received
U.S. Food and Drug Administration approval for clinical
application in the setting of tissue-engineered vascular grafts
and is expected to have an even vaster impact with regards
to TEHV (10), our study provides the first evidence to
facilitate this concept for the successful replacement of
aortic valves using a minimally invasive transcatheter ap-
proach. Its long-term durability proven, and taking into
account heart valve pioneer Dr. D. E. Harken’s “ten
commandments” (27) that define an optimal heart valve
prosthesis and thereby characterize a prosthesis with native
valve attributes, such TEHV may represent the next gen-
eration of heart valve substitutes potentially overcoming
some of the limitations of currently used bioprosthetic
valves.
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APPENDIX
For supplemental methods, figures, and videos, please see the online
version of this paper.
